US President Donald Trump on Friday blasted drugmakers and healthcare “middlemen” for making prescription drugs unaffordable for Americans, but healthcare stocks rose as experts said the administration avoided taking aggressive and direct measures to cut drug prices.
Trump said his administration would take aim at the “middlemen” in the drug industry who have become “very, very rich,” an apparent reference to health insurers and pharmacy benefit managers. He also said the pharmaceutical industry is making an “absolute fortune” at the expense of US taxpayers.
“Everyone involved in the broken system — the drugmakers, insurance companies, distributors, pharmacy benefit managers and many others — contribute to the problem,” Trump said.
Photo: AP
Shares of the major US companies in each of those sectors rose after the speech, with the S&P 500 healthcare sector, a broad gauge of large healthcare stocks, up 1.4 percent.
Trump also placed blame on foreign governments, which negotiate lower drug prices than in the US, saying they “extort” unreasonably low prices from US drugmakers.
Trump was speaking as his health deputies released a series of proposals to address high drug costs.
The US Department of Health and Human Services released what it called a blueprint titled “American Patients First” with details of its plan.
The administration’s immediate actions would include allowing commercial plans that administer Medicare Part D prescription drug benefits for seniors more power to negotiate prices with drugmakers, it said.
The US Food and Drug Administration would evaluate requiring drugmakers to include the list prices they set on medicines in their advertising.
Drugmakers argue that list prices do not reflect actual cost with discounts and rebates.
Some of the administration’s longer-term priorities include restricting use of rebates, creating incentives for drugmakers to lower list prices and investigating tools to address foreign government practices that it said could be harming innovation and driving up US prices.
Healthcare experts said Trump’s plan sounded like rhetoric rather than substantive change for an industry where prices rise substantially more than inflation each year.
“There’s not a big proposal here that is going to make a huge difference. There are a bunch of smaller technical changes,” Boston College associate professor of economics Sam Richardson said.
Regarding forcing other countries to pay more for drugs, Richardson said: “We don’t really have the policy levers to get that to happen.”
Secretary of Health and Human Services Alex Azar said during a White House briefing that many of the actions the government was considering would not require the US Congress, but could take place through executive action within months. He said it would take years to restructure the US drug system.
Healthcare stocks were volatile during Trump’s speech, with shares of companies involved in the pharmaceutical supply chain, such as Express Scripts Holding Co and CVS Health Corp, hitting session lows. However, those stocks quickly reversed course, with Express Scripts shares up 2.4 percent and CVS up 3 percent.
‘SWASTICAR’: Tesla CEO Elon Musk’s close association with Donald Trump has prompted opponents to brand him a ‘Nazi’ and resulted in a dramatic drop in sales Demonstrators descended on Tesla Inc dealerships across the US, and in Europe and Canada on Saturday to protest company chief Elon Musk, who has amassed extraordinary power as a top adviser to US President Donald Trump. Waving signs with messages such as “Musk is stealing our money” and “Reclaim our country,” the protests largely took place peacefully following fiery episodes of vandalism on Tesla vehicles, dealerships and other facilities in recent weeks that US officials have denounced as terrorism. Hundreds rallied on Saturday outside the Tesla dealership in Manhattan. Some blasted Musk, the world’s richest man, while others demanded the shuttering of his
Taiwan’s official purchasing managers’ index (PMI) last month rose 0.2 percentage points to 54.2, in a second consecutive month of expansion, thanks to front-loading demand intended to avoid potential US tariff hikes, the Chung-Hua Institution for Economic Research (CIER, 中華經濟研究院) said yesterday. While short-term demand appeared robust, uncertainties rose due to US President Donald Trump’s unpredictable trade policy, CIER president Lien Hsien-ming (連賢明) told a news conference in Taipei. Taiwan’s economy this year would be characterized by high-level fluctuations and the volatility would be wilder than most expect, Lien said Demand for electronics, particularly semiconductors, continues to benefit from US technology giants’ effort
ADVERSARIES: The new list includes 11 entities in China and one in Taiwan, which is a local branch of Chinese cloud computing firm Inspur Group The US added dozens of entities to a trade blacklist on Tuesday, the US Department of Commerce said, in part to disrupt Beijing’s artificial intelligence (AI) and advanced computing capabilities. The action affects 80 entities from countries including China, the United Arab Emirates and Iran, with the commerce department citing their “activities contrary to US national security and foreign policy.” Those added to the “entity list” are restricted from obtaining US items and technologies without government authorization. “We will not allow adversaries to exploit American technology to bolster their own militaries and threaten American lives,” US Secretary of Commerce Howard Lutnick said. The entities
Minister of Finance Chuang Tsui-yun (莊翠雲) yesterday told lawmakers that she “would not speculate,” but a “response plan” has been prepared in case Taiwan is targeted by US President Donald Trump’s reciprocal tariffs, which are to be announced on Wednesday next week. The Trump administration, including US Secretary of the Treasury Scott Bessent, has said that much of the proposed reciprocal tariffs would focus on the 15 countries that have the highest trade surpluses with the US. Bessent has referred to those countries as the “dirty 15,” but has not named them. Last year, Taiwan’s US$73.9 billion trade surplus with the US